ICDs in end-stage heart failure

BMJ Supportive and Palliative Care

Volumn 2, Issue 2, 2012, Pages 94-97

  Pettit, Stephen J ^a   Browne, Susan ^b   Hogg, Karen J ^a   Connelly, Derek T ^a   Gardner, Roy S ^a   May, Carl R ^c   Macleod, Una ^d   Mair, Frances S ^b  

^a GOLDEN JUBILEE NATIONAL HOSPITAL   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^d UNIVERSITY OF HULL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ETHICS; HEART FAILURE; HUMAN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; PALLIATIVE THERAPY; PATIENT; PUBLIC RELATIONS; TERMINAL CARE; TREATMENT WITHDRAWAL;

DEFIBRILLATORS, IMPLANTABLE; HEART FAILURE; HUMANS; INTERPROFESSIONAL RELATIONS; PALLIATIVE CARE; PATIENTS; TERMINAL CARE; WITHHOLDING TREATMENT;

EID: 84875151084     PISSN: 2045435X     EISSN: 20454368     Source Type: Journal    
DOI: 10.1136/bmjspcare-2011-000176     Document Type: Article

References (26)

1. Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation:endorsed by the Heart Rhythm Society. Circulation 2005;112:e154-e235.
2. Kadish A, Dyer A, Daubert JP, et al. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med 2004; 350: 2151-2158.
3. Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter defibrillator for congestive heart failure. N Engl J Med 2005; 352: 225-237.
4. Packer DL, Prutkin JM, Hellkamp AS, et al. Impact of implantable cardioverter defibrillator, amiodarone, and placebo on the mode of death in stable patients with heart failure: analysis from the sudden cardiac death in heart failure trial. Circulation 2009; 120: 2170-2176.
5. Levy WC, Lee KL, Hellkamp AS, et al. Maximizing survival benefit with primary prevention implantable cardioverter-defibrillator therapy in a heart failure population. Circulation 2009; 120: 835-842.
6. Zipes DP, Camm AJ, Borggrefe M, et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death) developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Europace 2006; 8: 746-837.
7. Whang W, Mittleman MA, Rich DQ, et al. Heart failure and the risk of shocks in patients with implantable cardioverter defibrillators: results from the Triggers Of Ventricular Arrhythmias (TOVA) study. Circulation 2004; 109: 1386-1391.
8. Mozaffarian D, Anker SD, Anand I, et al. Prediction of mode of death in heart failure:the Seattle Heart Failure Model. Circulation 2007; 116: 392-398.
9. Goldenberg I, Moss AJ, Hall WJ, et al. Causes and consequences of heart failure after prophylactic implantation of a defibrillator in the multicenter automatic defibrillator implantation trial II. Circulation 2006; 113: 2810-2817.
10. Goldenberg I, Gillespie J, Moss AJ, et al. Long-term benefit of primary prevention with an implantable cardioverter-defibrillator: an extended 8-year follow-up study of the Multicenter Automatic Defibrillator Implantation Trial II. Circulation 2010; 122: 1265-1271.
11. Koller MT, Schaer B, Wolbers M, et al. Death without prior appropriate implantable cardioverter-defibrillator therapy: a competing risk study. Circulation 2008; 117: 1918-1926.
12. Theuns DA, Schaer BA, Soliman OI, et al. The prognosis of implantable defibrillator patients treated with cardiac resynchronization therapy: comorbidity burden as predictor of mortality. Europace 2011; 13: 62-69.
13. Lewis WR, Luebke DL, Johnson NJ, et al. Withdrawing implantable defibrillator shock therapy in terminally ill patients. Am J Med 2006; 119: 892-896.
14. Goldstein NE, Lampert R, Bradley E, et al. Management of implantable cardioverter defibrillators in end-of-life care. Ann Intern Med 2004; 141: 835-838.
15. Beattie J. Implantable cardioverter defibrillators in patients who are reaching the end of life. London: British Heart Foundation, 2007.
16. Jaarsma T, Beattie JM, Ryder M, et al. Palliative care in heart failure:a position statement from the palliative care workshop of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2009; 11: 433-443.
17. Lampert R, Hayes DL, Annas GJ, et al. HRS Expert Consensus Statement on the Management of Cardiovascular Implantable Electronic Devices (CIEDs) in patients nearing end of life or requesting withdrawal of therapy. Heart Rhythm 2010; 7: 1008-1026.
18. Goldstein NE, Mehta D, Siddiqui S, et al. 'That's like an act of suicide' patients' attitudes toward deactivation of implantable defibrillators. J Gen Intern Med 2008;23 Suppl 1:7-12.
19. Marinskis G, van Erven L; EHRA Scientific Initiatives Committee. Deactivation of implanted cardioverter-defibrillators at the end of life: results of the EHRA survey. Europace 2010; 12: 1176-1177.
20. Goldstein N, Carlson M, Livote E, et al. Brief communication: Management of implantable cardioverter-defibrillators in hospice: A nationwide survey. Ann Intern Med 2010; 152: 296-299.
21. Barclay S, Momen N, Case-Upton S, et al. End-of-life care conversations with heart failure patients: a systematic literature review and narrative synthesis. Br J Gen Pract 2011;61:e49-e62.
22. Goldstein NE, Mehta D, Teitelbaum E, et al. "It's like crossing a bridge" complexities preventing physicians from discussing deactivation of implantable defibrillators at the end of life. J Gen Intern Med 2008;23 Suppl 1:2-6.
23. Kramer DB, Kesselheim AS, Brock DW, et al. Ethical and legal views of physicians regarding deactivation of cardiac implantable electrical devices: a quantitative assessment. Heart Rhythm 2010; 7: 1537-1542.
24. Goldstein N, Bradley E, Zeidman J, et al. Barriers to conversations about deactivation of implantable defibrillators in seriously ill patients: results of a nationwide survey comparing cardiology specialists to primary care physicians. J Am Coll Cardiol 2009; 54: 371-373.
25. Russo JE. Deactivation of ICDs at the end of life: a systematic review of clinical practices and provider and patient attitudes. Am J Nurs 2011; 111: 26-35.
26. Brunner-La Rocca H-P, Rickenbacher P, Muzzarelli S, et al. End-of-life preferences of elderly patients with chronic heart failure. Eur Heart J 2012; 33: 752-759.